Treat your growth hormone. Treat what stopped working.

Growth hormone therapy restores growth hormone activity to a level appropriate for your age, symptoms, and bloodwork — not a one-size dose, not a number off a chart. At Gambit it’s gated by a 60+ biomarker panel and reviewed by an internal medicine specialist before any prescription is written. Bloodwork isn’t a formality: hormone, metabolic, thyroid, and inflammatory markers all change what the right protocol looks like, and prescribing on symptoms alone misses the picture. Your protocol — direct replacement, or a peptide route that stimulates your body’s own production — is matched to your bloodwork, not chosen off a menu.

You don’t pick the protocol on your own — the bloodwork drives it, and your goals shape it. The path starts with a $100 eligibility assessment to confirm whether growth hormone therapy fits, then a comprehensive 60+ biomarker panel that surfaces the variables that decide protocol: hormone activity, thyroid, metabolic and inflammatory markers, and more. Your Gambit specialist weighs that against your symptoms, your goals, and how you want to live with treatment — direct replacement runs faster, the peptide route preserves your body’s own feedback loop. The recommendation is specific to you.

Some people with naturally higher growth hormone factors may have a slightly higher lifetime risk of certain cancers, but studies have not shown that raising growth hormone with treatment increases cancer risk or recurrence. Growth hormone therapy is used to bring growth hormone activity into a healthy range that supports how you actually feel — not to push levels into extremes. Your Gambit specialist will not prescribe it to anyone with active cancer, and cancer survivors should make the decision together with their oncologist.

Yes. The whole pathway is Canadian telehealth — intake online, bloodwork at a lab near you, asynchronous specialist review, prescription shipped to your door. Gambit serves patients all over Canada, and you’re not locked to a single lab partner: most patients use LifeLabs, Alberta Precision Laboratories, or Dynacare, but a hospital lab or whichever lab is closest to you works just as well. There’s no in-person clinic visit at any step. Message the health team when something needs a human.

Active cancer is a contraindication — your Gambit specialist will not prescribe growth hormone therapy in that case. If you’re a cancer survivor, the decision should be made together with your oncologist, who knows your tumour type, treatment history, and recurrence-risk profile. Tell the health team during your assessment so the specialist on your case can review the relevant history before any protocol is recommended. The eligibility step exists in part for moments like this: it’s where these conversations happen before any commitment.

Most patients notice the first shifts — energy, sleep quality, recovery — within the first few weeks. Body-composition changes settle in over months, and the published clinical literature on growth hormone replacement therapy reports up to 9% reduction in visceral fat at six months in treated groups. The bloodwork tells the rest of the story at your regular check-ins during your first few months on protocol, then on ongoing intervals. Response varies by individual; outcomes aren’t guaranteed.

The eligibility assessment is $100 — intake review, growth hormone factors bloodwork, and a clinical screen by an internal medicine specialist to confirm growth hormone therapy fits before you commit further. The full comprehensive is $485 + provincial percentage for a 60+ biomarker panel reviewed by your Gambit specialist, with a personalized protocol and ongoing bloodwork monitoring built in. Medications and pharmacy fulfillment are billed separately as you go. If you’re found clinically ineligible after the comprehensive, Gambit refunds 95% — and you keep the full read of your panel and the specialist’s insights, yours to take to any clinician.